CN101389213A - Pufa聚酮化合物合酶系统及其用途 - Google Patents
Pufa聚酮化合物合酶系统及其用途 Download PDFInfo
- Publication number
- CN101389213A CN101389213A CNA200480014646XA CN200480014646A CN101389213A CN 101389213 A CN101389213 A CN 101389213A CN A200480014646X A CNA200480014646X A CN A200480014646XA CN 200480014646 A CN200480014646 A CN 200480014646A CN 101389213 A CN101389213 A CN 101389213A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- pufa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010030975 Polyketide Synthases Proteins 0.000 title claims abstract description 873
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 854
- 244000005700 microbiome Species 0.000 claims abstract description 227
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 203
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 176
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 176
- 238000000034 method Methods 0.000 claims abstract description 101
- 230000000975 bioactive effect Effects 0.000 claims abstract description 42
- 235000003869 genetically modified organism Nutrition 0.000 claims abstract description 13
- 150000001413 amino acids Chemical group 0.000 claims description 281
- 108090000623 proteins and genes Proteins 0.000 claims description 260
- 241000233671 Schizochytrium Species 0.000 claims description 230
- 239000002773 nucleotide Substances 0.000 claims description 194
- 125000003729 nucleotide group Chemical group 0.000 claims description 193
- 241001467333 Thraustochytriaceae Species 0.000 claims description 182
- 230000004071 biological effect Effects 0.000 claims description 162
- 241000894006 Bacteria Species 0.000 claims description 157
- 102000004169 proteins and genes Human genes 0.000 claims description 144
- 238000012239 gene modification Methods 0.000 claims description 122
- 230000005017 genetic modification Effects 0.000 claims description 122
- 235000013617 genetically modified food Nutrition 0.000 claims description 122
- 101710146995 Acyl carrier protein Proteins 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 70
- 102000004190 Enzymes Human genes 0.000 claims description 67
- 108090000790 Enzymes Proteins 0.000 claims description 66
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 63
- 241000233675 Thraustochytrium Species 0.000 claims description 62
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 62
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 62
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 62
- 230000008859 change Effects 0.000 claims description 59
- 239000012634 fragment Substances 0.000 claims description 58
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 53
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 50
- 230000004048 modification Effects 0.000 claims description 48
- 238000012986 modification Methods 0.000 claims description 48
- 239000000047 product Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 42
- 108700016155 Acyl transferases Proteins 0.000 claims description 33
- 102000057234 Acyl transferases Human genes 0.000 claims description 31
- 108700026244 Open Reading Frames Proteins 0.000 claims description 28
- 238000006555 catalytic reaction Methods 0.000 claims description 27
- 239000007795 chemical reaction product Substances 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 108010019608 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase Proteins 0.000 claims description 24
- 102100037149 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial Human genes 0.000 claims description 24
- 150000004665 fatty acids Chemical class 0.000 claims description 24
- 238000001890 transfection Methods 0.000 claims description 24
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 23
- 230000012010 growth Effects 0.000 claims description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 20
- 229930195729 fatty acid Natural products 0.000 claims description 20
- 239000000194 fatty acid Substances 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 claims description 18
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 claims description 18
- 231100000350 mutagenesis Toxicity 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 18
- 230000008034 disappearance Effects 0.000 claims description 16
- 238000002703 mutagenesis Methods 0.000 claims description 16
- 102000004357 Transferases Human genes 0.000 claims description 14
- 108090000992 Transferases Proteins 0.000 claims description 14
- 101710129019 Long-chain acyl-[acyl-carrier-protein] reductase Proteins 0.000 claims description 12
- 150000001336 alkenes Chemical class 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 235000021342 arachidonic acid Nutrition 0.000 claims description 11
- 229940114079 arachidonic acid Drugs 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 241000003482 Japonochytrium Species 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 241000333170 Shewanella japonica Species 0.000 claims description 9
- 241000947863 Shewanella olleyana Species 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 9
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 claims description 8
- 108700037654 Acyl carrier protein (ACP) Proteins 0.000 claims description 8
- 102000048456 Acyl carrier protein (ACP) Human genes 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000233673 Schizochytrium aggregatum Species 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 241000003595 Aurantiochytrium limacinum Species 0.000 claims description 6
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 235000021290 n-3 DPA Nutrition 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 5
- 235000013350 formula milk Nutrition 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 235000020244 animal milk Nutrition 0.000 claims description 4
- 230000001773 anti-convulsant effect Effects 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940037467 helicobacter pylori Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241000003597 Schizochytrium minutum Species 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 2
- 206010036600 Premature labour Diseases 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000002824 peroxisome Anatomy 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 208000026440 premature labor Diseases 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 39
- 238000004519 manufacturing process Methods 0.000 abstract description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 278
- 235000018102 proteins Nutrition 0.000 description 125
- 235000001014 amino acid Nutrition 0.000 description 120
- 229940024606 amino acid Drugs 0.000 description 117
- 241000196324 Embryophyta Species 0.000 description 64
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 51
- 230000006870 function Effects 0.000 description 48
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 description 41
- 241001491670 Labyrinthula Species 0.000 description 34
- 241000195493 Cryptophyta Species 0.000 description 33
- 239000000523 sample Substances 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 26
- 102000000157 3-oxoacyl-(acyl-carrier-protein) reductase Human genes 0.000 description 25
- 108010055468 3-oxoacyl-(acyl-carrier-protein) reductase Proteins 0.000 description 25
- 241000206602 Eukaryota Species 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 241001491672 Labyrinthulaceae Species 0.000 description 24
- 238000009396 hybridization Methods 0.000 description 23
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 20
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 20
- 241000233866 Fungi Species 0.000 description 20
- 230000000977 initiatory effect Effects 0.000 description 20
- 125000002252 acyl group Chemical group 0.000 description 17
- 241000588807 Bordetella Species 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 241000294598 Moritella marina Species 0.000 description 15
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 241001467308 Labyrinthuloides Species 0.000 description 14
- 241001466451 Stramenopiles Species 0.000 description 14
- 241001462977 Elina Species 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 241000233654 Oomycetes Species 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000008521 reorganization Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 9
- 230000008676 import Effects 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 241000003610 Aplanochytrium Species 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 210000003495 flagella Anatomy 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 7
- 241000598397 Schizochytrium sp. Species 0.000 description 7
- 241001491678 Ulkenia Species 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 7
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- JDMUPRLRUUMCTL-VIFPVBQESA-N D-pantetheine 4'-phosphate Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS JDMUPRLRUUMCTL-VIFPVBQESA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 241001491708 Macrocystis Species 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000009849 deactivation Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- -1 methyl carbon Chemical compound 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MENFZXMQSYYVRK-CRCGJGBYSA-N (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MENFZXMQSYYVRK-CRCGJGBYSA-N 0.000 description 4
- 101710142619 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ Proteins 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- 241000206751 Chrysophyceae Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000223924 Eimeria Species 0.000 description 4
- 241000224421 Heterolobosea Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 4
- 241000144181 Thraustochytrium aureum Species 0.000 description 4
- 241000817756 Thraustochytrium roseum Species 0.000 description 4
- 241001298230 Thraustochytrium sp. Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 125000001924 fatty-acyl group Chemical group 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 150000004671 saturated fatty acids Chemical class 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000224489 Amoeba Species 0.000 description 3
- 241000192700 Cyanobacteria Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108091029795 Intergenic region Proteins 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 241000108056 Monas Species 0.000 description 3
- 241000192656 Nostoc Species 0.000 description 3
- 241001138688 Parietichytrium sarkarianum Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 241000607568 Photobacterium Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241001138690 Sicyoidochytrium minutum Species 0.000 description 3
- 241000003603 Thraustochytrium striatum Species 0.000 description 3
- 241000719329 Trentepohlia Species 0.000 description 3
- 241001501884 Ulkenia profunda Species 0.000 description 3
- 241001298226 Ulkenia sp. Species 0.000 description 3
- 241000003605 Ulkenia visurgensis Species 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- QTBSBXVTEAMEQO-HQMMCQRPSA-N acetic acid Chemical compound C[14C](O)=O QTBSBXVTEAMEQO-HQMMCQRPSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 125000001721 carboxyacetyl group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006126 farnesylation Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000018875 hypoxemia Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 2
- 241000157880 Acrasis Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 241000224495 Dictyostelium Species 0.000 description 2
- 241000199914 Dinophyceae Species 0.000 description 2
- 108010028143 Dioxygenases Proteins 0.000 description 2
- 102000016680 Dioxygenases Human genes 0.000 description 2
- 241000235577 Entomophthorales Species 0.000 description 2
- 241000195620 Euglena Species 0.000 description 2
- 241000195623 Euglenida Species 0.000 description 2
- 241000224472 Eustigmatophyceae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000200287 Gymnodinium Species 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241001467310 Labyrinthuloides minuta Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241001337863 Monoblepharidales Species 0.000 description 2
- 241000235575 Mortierella Species 0.000 description 2
- 241000235388 Mucorales Species 0.000 description 2
- 108010093369 Multienzyme Complexes Proteins 0.000 description 2
- 102000002568 Multienzyme Complexes Human genes 0.000 description 2
- 241000221960 Neurospora Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000199911 Peridinium Species 0.000 description 2
- 241000233678 Peronosporales Species 0.000 description 2
- 241000243335 Prostomatea Species 0.000 description 2
- 241000233656 Saprolegniales Species 0.000 description 2
- 241000863430 Shewanella Species 0.000 description 2
- 241001223867 Shewanella oneidensis Species 0.000 description 2
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 2
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000003599 Thraustochytrium aggregatum Species 0.000 description 2
- 241001501879 Thraustochytrium kinnei Species 0.000 description 2
- 241000323188 Thraustochytrium motivum Species 0.000 description 2
- 241000003604 Thraustochytrium pachydermum Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000206764 Xanthophyceae Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 102000045404 acyltransferase activity proteins Human genes 0.000 description 2
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 244000038559 crop plants Species 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000004050 enoyl group Chemical group 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 108020003068 nitronate monooxygenase Proteins 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000013823 prenylation Effects 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- DJCQJZKZUCHHAL-UHFFFAOYSA-N (Z)-9-Pentadecensaeure Natural products CCCCCC=CCCCCCCCC(O)=O DJCQJZKZUCHHAL-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 241000921240 Acantharea Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100036426 Acid phosphatase type 7 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241001466460 Alveolata Species 0.000 description 1
- 241000848498 Anthophysa Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000178280 Aureococcus Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000235430 Blastocladiales Species 0.000 description 1
- 241001138694 Botryochytrium radiatum Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 241000966233 Bumilleria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241001455092 Centroheliozoa Species 0.000 description 1
- 241000200138 Ceratium Species 0.000 description 1
- 241001139381 Cercomonadida Species 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241001134734 Choanoflagellida Species 0.000 description 1
- 241000384555 Chromulinales Species 0.000 description 1
- 241001219477 Chroococcus Species 0.000 description 1
- 241001491656 Chrysochromulina Species 0.000 description 1
- 241000534675 Chrysomeridales Species 0.000 description 1
- 241000235441 Chytridiales Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241001633026 Coenocystis Species 0.000 description 1
- 241001312435 Coenonia Species 0.000 description 1
- 241000248331 Colpodea Species 0.000 description 1
- 241000199913 Crypthecodinium Species 0.000 description 1
- 241000195618 Cryptomonas Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241000146404 Developayella Species 0.000 description 1
- 241001221643 Diacronema Species 0.000 description 1
- 241001494734 Dictyochales Species 0.000 description 1
- 241001408851 Dinobryaceae Species 0.000 description 1
- 241000391095 Dinobryon Species 0.000 description 1
- 241000224460 Diplomonadida Species 0.000 description 1
- 241000196133 Dryopteris Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001442148 Goniomonas Species 0.000 description 1
- 241001492416 Gromia Species 0.000 description 1
- 241001059231 Guttulinaceae Species 0.000 description 1
- 241001059232 Guttulinopsis Species 0.000 description 1
- 241001139448 Gymnophrys Species 0.000 description 1
- 241000866505 Gyrodinium Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241001218494 Helkesimastix Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001466486 Hibberdiales Species 0.000 description 1
- 101000928881 Homo sapiens Acid phosphatase type 7 Proteins 0.000 description 1
- 101000620894 Homo sapiens Lysophosphatidic acid phosphatase type 6 Proteins 0.000 description 1
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
- 101000620880 Homo sapiens Tartrate-resistant acid phosphatase type 5 Proteins 0.000 description 1
- 101001122914 Homo sapiens Testicular acid phosphatase Proteins 0.000 description 1
- 241001306467 Hydrurales Species 0.000 description 1
- 101150111320 KS gene Proteins 0.000 description 1
- 241000415370 Katablepharis Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001254607 Leander Species 0.000 description 1
- 241000321520 Leptomitales Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 241000248342 Litostomatea Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100022916 Lysophosphatidic acid phosphatase type 6 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 1
- 241000180113 Monodus Species 0.000 description 1
- 241000972792 Multicilia Species 0.000 description 1
- 241001467460 Myxogastria Species 0.000 description 1
- 241000243338 Nassophorea Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000424623 Nostoc punctiforme Species 0.000 description 1
- 241001478892 Nostoc sp. PCC 7120 Species 0.000 description 1
- 241000199478 Ochromonas Species 0.000 description 1
- 241000243200 Oligohymenophorea Species 0.000 description 1
- 241001622808 Olisthodiscus Species 0.000 description 1
- 241001465255 Opisthokonta Species 0.000 description 1
- 241000200172 Oxyrrhis Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000392493 Paramyxea Species 0.000 description 1
- 241001508529 Paraphysomonas Species 0.000 description 1
- 241000472328 Parmales Species 0.000 description 1
- 241001494726 Pedinellales Species 0.000 description 1
- 241001494897 Pelagomonas Species 0.000 description 1
- 101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 1
- 241000206731 Phaeodactylum Species 0.000 description 1
- 241000688179 Phaeodarea Species 0.000 description 1
- 241001260361 Photobacterium profundum Species 0.000 description 1
- 241001503943 Phyllopharyngea Species 0.000 description 1
- 241000593473 Platychrysis Species 0.000 description 1
- 241000958364 Pohlia Species 0.000 description 1
- 241000921210 Polycystinea Species 0.000 description 1
- 241000736236 Polysphondylium Species 0.000 description 1
- 241000015243 Poterioochromonas Species 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 101710089165 Protein white Proteins 0.000 description 1
- 241001491792 Prymnesium Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000203296 Reticulomyxa Species 0.000 description 1
- 241000520590 Reticulosphaera Species 0.000 description 1
- 241001501882 Rhodomonas Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000700673 Rhombozoa Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000708896 Sappinia Species 0.000 description 1
- 241000193082 Sarcinochrysidales Species 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 241000557283 Shewanella gelidimarina Species 0.000 description 1
- 241000589973 Spirochaeta Species 0.000 description 1
- 241001467592 Spirotrichea Species 0.000 description 1
- 241000028617 Spumella Species 0.000 description 1
- 241000546140 Stigeoclonium Species 0.000 description 1
- 101000912941 Streptococcus gordonii DegV domain-containing protein Proteins 0.000 description 1
- 101000691656 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA1, modules 1 and 2 Proteins 0.000 description 1
- 101000691655 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA2, modules 3 and 4 Proteins 0.000 description 1
- 101000691658 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA3, module 5 Proteins 0.000 description 1
- 101001125873 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA4, module 6 Proteins 0.000 description 1
- 241001531212 Suctoria Species 0.000 description 1
- 241000199481 Synura Species 0.000 description 1
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 description 1
- 102100028526 Testicular acid phosphatase Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 241001439624 Trichina Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000508876 Tubulinea Species 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001482200 Vaucheria geminata Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 241001555658 Xenophyophorea Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241001314279 Zoopagales Species 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical group CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000003001 amoeba Anatomy 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-N cis-vaccenic acid Chemical compound CCCCCC\C=C/CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-FPLPWBNLSA-N 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GPWDPLKISXZVIE-UHFFFAOYSA-N cyclo[18]carbon Chemical compound C1#CC#CC#CC#CC#CC#CC#CC#CC#C1 GPWDPLKISXZVIE-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010064739 ent-kaurene synthetase B Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 101150078207 fabA gene Proteins 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019867 fractionated palm kernal oil Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000006130 geranylgeranylation Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000009569 heterotrophic growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
Abstract
Description
Claims (114)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45797903P | 2003-03-26 | 2003-03-26 | |
US60/457,979 | 2003-03-26 | ||
PCT/US2004/009323 WO2004087879A2 (en) | 2003-03-26 | 2004-03-26 | Pufa polyketide synthase systems and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101389213A true CN101389213A (zh) | 2009-03-18 |
CN101389213B CN101389213B (zh) | 2014-05-28 |
Family
ID=33131738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480014646.XA Expired - Fee Related CN101389213B (zh) | 2003-03-26 | 2004-03-26 | Pufa聚酮化合物合酶系统及其用途 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1623008B1 (zh) |
JP (3) | JP2007524377A (zh) |
KR (3) | KR101234199B1 (zh) |
CN (1) | CN101389213B (zh) |
AU (2) | AU2004225485B2 (zh) |
BR (1) | BRPI0409046A (zh) |
CA (1) | CA2520396C (zh) |
ES (1) | ES2516641T3 (zh) |
HK (1) | HK1088632A1 (zh) |
IL (1) | IL200625A0 (zh) |
MX (2) | MXPA05010214A (zh) |
WO (1) | WO2004087879A2 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340742A (en) | 1988-09-07 | 1994-08-23 | Omegatech Inc. | Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids |
US6566583B1 (en) | 1997-06-04 | 2003-05-20 | Daniel Facciotti | Schizochytrium PKS genes |
US8003772B2 (en) * | 1999-01-14 | 2011-08-23 | Martek Biosciences Corporation | Chimeric PUFA polyketide synthase systems and uses thereof |
US7247461B2 (en) | 1999-01-14 | 2007-07-24 | Martek Biosciences Corporation | Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof |
US7211418B2 (en) | 1999-01-14 | 2007-05-01 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
US7217856B2 (en) | 1999-01-14 | 2007-05-15 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
EP2341127B1 (en) | 2000-01-28 | 2015-05-27 | DSM IP Assets B.V. | Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors |
CA2614095A1 (en) | 2005-07-01 | 2007-01-11 | Martek Biosciences Corporation | Polyunsaturated fatty acid-containing oil product and uses and production thereof |
GB0603160D0 (en) * | 2006-02-16 | 2006-03-29 | Rothamsted Res Ltd | Nucleic acid |
JP2009529891A (ja) | 2006-03-15 | 2009-08-27 | マーテック バイオサイエンシーズ コーポレーション | 多価不飽和脂肪酸を含む植物種子油 |
CA2662260C (en) * | 2006-08-29 | 2015-10-27 | Martek Biosciences Corporation | Use of dpa(n-6) oils in infant formula |
EP2405018A4 (en) * | 2009-03-04 | 2013-02-20 | Univ Miyazaki | METHOD FOR DETERMINING FATTY ACID SYNTHESIS PATHWAYS OF A MICROORGANISM, AND PCR PRIMER GROUP USED IN SAID METHOD |
EP2408795B1 (en) * | 2009-03-16 | 2017-04-19 | DSM IP Assets B.V. | Protein production in microorganisms of the phylum labyrinthulomycota |
TWI600762B (zh) | 2009-03-19 | 2017-10-01 | Dsm智慧財產有限公司 | 多不飽和脂肪酸合成酶核酸分子及多肽,組成物,以及其製造方法與用途 |
EP2614829A1 (en) * | 2012-01-11 | 2013-07-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons |
KR101570771B1 (ko) | 2013-11-18 | 2015-11-23 | 대한민국 | 고도불포화지방산 생합성을 위한 재조합 벡터 및 이를 이용하여 제작된 형질전환 식물체 |
WO2016111368A1 (ja) * | 2015-01-09 | 2016-07-14 | 国立大学法人宮崎大学 | ヤブレツボカビ類を用いたリグニン分解活性を有するタンパク質の製造方法 |
BR112018073164A2 (pt) * | 2016-05-12 | 2019-04-30 | Dsm Ip Assets Bv | método de aumento de produção de ácidos graxos poli-insaturados ômega-3 em microalgas |
JPWO2020032258A1 (ja) * | 2018-08-10 | 2021-08-12 | 協和発酵バイオ株式会社 | 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 |
EP3835410A4 (en) * | 2018-08-10 | 2022-05-18 | Kyowa Hakko Bio Co., Ltd. | EICOSAPENTAIC ACID PRODUCING MICROORGANISM AND PROCESS FOR PRODUCTION OF EICOSAPENTAIC ACID |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340742A (en) * | 1988-09-07 | 1994-08-23 | Omegatech Inc. | Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids |
US6566583B1 (en) * | 1997-06-04 | 2003-05-20 | Daniel Facciotti | Schizochytrium PKS genes |
IN1998CH01219A (en) * | 1997-06-04 | 2005-03-04 | Calgene Llc | Production of polyunsaturated fatty acid by expression of polyketide-like synthesis genes in plants |
US6677145B2 (en) * | 1998-09-02 | 2004-01-13 | Abbott Laboratories | Elongase genes and uses thereof |
US7247461B2 (en) * | 1999-01-14 | 2007-07-24 | Martek Biosciences Corporation | Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof |
PT1322752E (pt) * | 2000-09-28 | 2010-05-06 | Bioriginal Food & Science Corp | Fad4, fad5, fad5-2 e fad6, novos membros da família de dessaturases de ácidos gordos e susas utilizações |
TWI337619B (en) * | 2001-04-16 | 2011-02-21 | Martek Biosciences Corp | Pufa polyketide synthase systems and uses thereof |
JP2005508140A (ja) * | 2001-05-21 | 2005-03-31 | エコピア バイオサイエンシーズ インク | エンジイン環構造の生合成に関与する遺伝子及びタンパク質 |
-
2004
- 2004-03-26 MX MXPA05010214A patent/MXPA05010214A/es active IP Right Grant
- 2004-03-26 MX MX2011000195A patent/MX341785B/es unknown
- 2004-03-26 KR KR1020127012277A patent/KR101234199B1/ko not_active IP Right Cessation
- 2004-03-26 BR BRPI0409046-2A patent/BRPI0409046A/pt not_active Application Discontinuation
- 2004-03-26 KR KR1020127026179A patent/KR101234200B1/ko not_active IP Right Cessation
- 2004-03-26 AU AU2004225485A patent/AU2004225485B2/en not_active Expired
- 2004-03-26 ES ES04758405.7T patent/ES2516641T3/es not_active Expired - Lifetime
- 2004-03-26 WO PCT/US2004/009323 patent/WO2004087879A2/en active Application Filing
- 2004-03-26 EP EP04758405.7A patent/EP1623008B1/en not_active Expired - Lifetime
- 2004-03-26 JP JP2006509351A patent/JP2007524377A/ja not_active Withdrawn
- 2004-03-26 CA CA2520396A patent/CA2520396C/en not_active Expired - Lifetime
- 2004-03-26 KR KR1020057018067A patent/KR101234198B1/ko not_active IP Right Cessation
- 2004-03-26 CN CN200480014646.XA patent/CN101389213B/zh not_active Expired - Fee Related
-
2006
- 2006-04-13 HK HK06104546.5A patent/HK1088632A1/zh not_active IP Right Cessation
-
2008
- 2008-11-21 AU AU2008249169A patent/AU2008249169B2/en not_active Ceased
-
2009
- 2009-08-27 IL IL200625A patent/IL200625A0/en unknown
-
2013
- 2013-02-28 JP JP2013038130A patent/JP5890791B2/ja not_active Expired - Lifetime
-
2015
- 2015-09-18 JP JP2015185444A patent/JP6134361B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN101389213B (zh) | 2014-05-28 |
MX341785B (es) | 2016-09-01 |
KR101234198B1 (ko) | 2013-02-19 |
EP1623008B1 (en) | 2014-07-30 |
JP2016000048A (ja) | 2016-01-07 |
JP2007524377A (ja) | 2007-08-30 |
AU2004225485B2 (en) | 2008-08-21 |
JP2013143945A (ja) | 2013-07-25 |
JP5890791B2 (ja) | 2016-03-22 |
EP1623008A4 (en) | 2009-05-27 |
HK1088632A1 (zh) | 2006-11-10 |
BRPI0409046A (pt) | 2006-04-18 |
KR20060006014A (ko) | 2006-01-18 |
AU2008249169A1 (en) | 2008-12-11 |
KR20120097502A (ko) | 2012-09-04 |
KR20120123726A (ko) | 2012-11-09 |
KR101234199B1 (ko) | 2013-02-20 |
MXPA05010214A (es) | 2005-12-14 |
IL200625A0 (en) | 2011-07-31 |
AU2004225485A1 (en) | 2004-10-14 |
KR101234200B1 (ko) | 2013-02-19 |
WO2004087879A2 (en) | 2004-10-14 |
AU2008249169B2 (en) | 2012-03-15 |
WO2004087879A3 (en) | 2008-07-24 |
EP1623008A2 (en) | 2006-02-08 |
JP6134361B2 (ja) | 2017-05-24 |
CA2520396C (en) | 2016-08-09 |
ES2516641T3 (es) | 2014-10-31 |
CA2520396A1 (en) | 2004-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6134361B2 (ja) | Pufaポリケチドシンターゼ系およびこれらの使用 | |
JP5806259B2 (ja) | Pufaポリケチドシンターゼ系およびそれらの使用方法 | |
US7211418B2 (en) | PUFA polyketide synthase systems and uses thereof | |
US7259295B2 (en) | PUFA polyketide synthase systems and uses thereof | |
CN101437950A (zh) | Pufa聚酮合酶系统及其用途 | |
JP2005510203A6 (ja) | Pufaポリケチドシンターゼ系およびそれらの使用方法 | |
AU2012203480A1 (en) | PUFA polyketide synthase systems and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DSM IP ASSET LLP Free format text: FORMER OWNER: MARTEK BIOSCIENCES BOULDER CORP. Effective date: 20121115 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121115 Address after: Holland Heerlen Applicant after: DSM IP asset company Address before: American Maryland Applicant before: Martek Biosciences Corp. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140528 Termination date: 20150326 |
|
EXPY | Termination of patent right or utility model |